Company / PP&E per Share
Compass Therapeutics, Inc. PP&E per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$0.00
FY2024
5-year range
$0.00 / $0.04
FY2020-FY2024
Trend
-63.6%
vs FY2023
Sector context
#179 of 193
Health Care
What the data says
Among 193 Health Care companies, Compass Therapeutics, Inc. is in the bottom 7% for pp&e per share. PP&E per Share has declined for 5 consecutive years, from $0.56 in FY2019 to $0.00 in FY2024.
Based on SEC 10-K filings.
0.00 in FY2024 with a 5-year CAGR of -66.0%.
Declined from $0.01 to $0.00 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -58.4%
- 5-Year CAGR
- -66.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 193This company $0.00 Sector average $18.71
▼
-100.0% below sector average
Key checks
Key Insights
- Compass Therapeutics, Inc.'s pp&e per share has declined for 5 consecutive years.
- In FY2024, pp&e per share decreased 63.6% year-over-year.
- Ranks #179 out of 193 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.00 | -63.6% |
| FY2023 | $0.01 | -43.3% |
| FY2022 | $0.01 | -65.2% |
| FY2021 | $0.04 | -2.5% |
| FY2020 | $0.04 | -93.5% |
| FY2019 | $0.56 | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026